Isis Pharmaceuticals Inc. (ISIS) announced data from its Phase 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes on Sunday. The study showed that patients treated with ISIS-APOCIIIRx experienced an 88% reduction in apolipoprotein C-III, a 72% reduction in triglyceride levels, a 40% increase in high-density lipoprotein cholesterol.
Isis Pharmaceuticals gapped open higher Monday morning and is now up 2.52 at $24.51. The stock has risen above a 2-week range and has set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.